EN DE
Watch Kestra Medical Technologies, Ltd. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Kestra Medical Technologies, Ltd. (KMTS) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Kestra Medical Technologies, Ltd. stock $20.23, price $29.55, that is 31.5% below the price, quality 36 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · ISIN BMG524411052

KM Kestra Medical Technologies, Ltd. logo Thin data Nov 10, 2026

Kestra Medical Technologies, Ltd.

KMTS · US
Expensive, weak quality

Our calculation puts a fair price 32% below what the stock costs today.

Low debt
Revenue last quarter +60% vs. a year ago.
Mixed Growth (revenue 3y +131.9 %/yr in USD)
Insiders sold $13.5M (6M)
Fair value $20.23 · Overvalued
Quality 36/100
Loss-making · -140.4% net margin (TTM)
Negative free cash flow
Trails peers (1/11)
Narrow moat 12/100
Thin data
Estimate
Watch Kestra Medical Technologies, Ltd. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$30.61 $14.46 Fair Value $20.23 Mar 2025 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

20‑month range $14.46 – $30.61 · fair‑value band $15.17 – $25.28 · the $29.55 price screens above the $20.23 fair value. As of Nov 10, 2026.

Follow Kestra Medical Technologies, Ltd. Common Stock in your weekly email

Every Wednesday you see whether Kestra Medical Technologies, Ltd. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected.

Show moreShow less

The company's develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution.

Its platform provides ASSURE WCD, a wearable cardioverter defibrillator used to protect patients at an elevated risk of sudden cardiac arrest; and a suite of integrated digital solutions and services that enable enhanced patient and provider engagement and oversight with the objective of improving patient outcomes.

The company was founded in 2014 and is based in Kirkland, Washington.

Stock analysis

Kestra Medical Technologies, Ltd. (KMTS) currently trades at $29.55, while our estimate is $20.23, 32% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $15.17 (bear) to $25.28 (bull), the price of $29.55 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Kestra Medical Technologies, Ltd. Common Stock reported revenue of $95.1M in FY2026 versus $0 in FY2021. Reported net income was −$132M in FY2026.

Key figures

Market cap $1.7B Small · P/S ratio 16.1 · EPS (TTM) $−2.67 · Dividend yield 0.0% · Net margin −140% · Return on equity −73.7% · Return on assets (EBIT) −115% (5-year average) · Operating margin −122%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (medium confidence).

What moves the price

The share trades about 3% below its 52-week high and 65% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −32%, KMTS screens cheaper than that median.

Fair Value

Bear $15.17 Fair Value $20.23 Bull $25.28
Price $29.55 · Downside -31.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 36/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 90
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 95
Debt, balance sheet and risk of trouble
Investment 0
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 59
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 70
Distance to the 52-week high, does not count
New shares 12
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 11 officers or directors sold shares worth $13.5M and none bought.

  • SaleTimothy P. MoranChief Business Officer2× since Jul 30, 2026: 18,448 shares, avg. $24.00$442,686Nov 3, 2026
  • SaleVaseem MahboobChief Financial Officer4× since Jul 30, 2026: 130,970 shares, avg. $28.10$3.7MOct 29, 2026
  • SaleTraci S UmbergerOfficer, Director5× since Dec 29, 2025: 166,309 shares, avg. $27.05$4.5MOct 27, 2026
  • SaleBrian Daniel WebsterOfficer, Director12× since Dec 29, 2025: 231,722 shares, avg. $23.79$5.5MOct 20, 2026
  • SaleRaymond W CohenDirector3,330 shares at $29.28$97,504Sep 30, 2026
  • SaleElizabeth KwoDirector4,010 shares at $24.26$97,283Sep 21, 2026
  • SaleJeffrey Lawrence SchwartzDirector, 10% owner3,890 shares at $25.18$97,950Sep 8, 2026
  • SaleMary Kay LadoneDirector3,908 shares at $25.20$98,482Sep 8, 2026
  • SaleKevin C ReillyDirector2,932 shares at $25.13$73,681Sep 8, 2026
  • SaleConor HanleyDirector5,694 shares at $25.25$143,774Sep 8, 2026

Plus 2 more entries from the last 12 months.

Plus 21 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 26/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+59.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+131.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,054.0% (2023) → −141.6% (2026)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2026 is a loss year, no rate is defined from a loss
not computed

KMTS screens overvalued: fair value 32% below the price. Compare with Intuitive Surgical, Inc →

Compare Kestra Medical Technologies, Ltd. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 196 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −31.5% · Below median
Profitability
Return on assets −36.7% · Bottom 25%
Net margin (12 months) −140.4% · Bottom 25%
Operating margin (12 months) −121.6% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 59.9% · Top 25%
Dividend yield (12 months) 0.0% · Bottom 25%
Balance sheet
Debt / equity 0.16× · Above median

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 6.65× · Priciest 25%
P/S (12 months) 16.17× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 21
FUTURE (revenue growth)100 · sector 40
PAST (return on equity)0 · sector 26
HEALTH (low debt)92 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.08 $131.27 +46% vs KMTS
EssilorLuxottica Société anonyme EL €187.60 €196.22 +5% vs KMTS
Intuitive Surgical, Inc ISRG $450.04 $353.90 −21% vs KMTS
Medline Inc MDLN $40.91 $28.59 −30% vs KMTS
Alcon Inc ALC CHF 61.88 CHF 34.06 −45% vs KMTS
Becton, Dickinson and Company BDX $212.61 $97.80 −54% vs KMTS
Straumann Holding STMN CHF 106.85 CHF 45.50 −57% vs KMTS
West Pharmaceutical Services, Inc WST $412.55 $139.22 −66% vs KMTS
Sartorius Stedim Biotech S.A DIM €223.40 €54.82 −75% vs KMTS
Sartorius Aktiengesellschaft SRT €227.00 €42.50 −81% vs KMTS

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Kestra Medical Technologies, Ltd. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Kestra Medical Technologies, Ltd. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/KMTS

Frequently asked questions

Is Kestra Medical Technologies, Ltd. (KMTS) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $20.23 versus a price of $29.55, about 32% lower (overvalued).
What is the fair value of KMTS?
Our estimate for Kestra Medical Technologies, Ltd. is $20.23 (as of Nov 10, 2026), built from audited fundamentals. The current price: $29.55.
What is the quality score of KMTS?
Kestra Medical Technologies, Ltd. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kestra Medical Technologies, Ltd. (KMTS)?
Our calculated price target is the estimate of $20.23 (as of Nov 10, 2026). Cautious scenario $15.17, optimistic scenario $25.28. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Kestra Medical Technologies, Ltd. Common Stock stock forecast for 2026?
Our estimate puts fair value at $20.23, about 32% lower versus a price of $29.55 (overvalued). Cautious scenario $15.17, optimistic scenario $25.28. The calculation is refreshed regularly with new filings.
What is the revenue of Kestra Medical Technologies, Ltd. (KMTS)?
Kestra Medical Technologies, Ltd. reported trailing-twelve-month revenue of about $107M (latest available figure, as of Nov 10, 2026).
Does Kestra Medical Technologies, Ltd. Common Stock pay a dividend?
Kestra Medical Technologies, Ltd. currently shows a dividend yield of 0.02% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Kestra Medical Technologies, Ltd. (KMTS)?
Kestra Medical Technologies, Ltd. has a dividend yield of 0.0%.
What is the intrinsic value of Kestra Medical Technologies, Ltd. (KMTS)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kestra Medical Technologies, Ltd. it is $20.23 per share (as of Nov 10, 2026), against a price of $29.55.
Is Kestra Medical Technologies, Ltd. Common Stock stock overvalued or undervalued in 2026?
As of Nov 10, 2026, KMTS trades above its calculated fair value: price $29.55, fair value $20.23, a gap of about −32% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KMTS?
No. The price is what the market pays today ($29.55); the fair value is what the company's own numbers justify ($20.23). For Kestra Medical Technologies, Ltd. the two are $9.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kestra Medical Technologies, Ltd. Common Stock worth?
The market values Kestra Medical Technologies, Ltd. at about $1.7B (market capitalisation, as of Nov 10, 2026). Per share that is $29.55; our models calculate a fair value of $20.23 per share.
What do the bullish and bearish scenarios say about KMTS?
Our models span a range for Kestra Medical Technologies, Ltd.: cautious scenario $15.17, base $20.23, optimistic $25.28 per share (as of Nov 10, 2026, price $29.55). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kestra Medical Technologies, Ltd. (KMTS)?
Balance-sheet figures for Kestra Medical Technologies, Ltd. (as of Nov 10, 2026): return on equity −73.7%, debt of 0.16 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is KMTS from its 52-week high?
Kestra Medical Technologies, Ltd. trades at $29.55, about 3% below its 52-week high of $30.61 and 65% above the low of $17.87 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $20.23 is for.
Which stocks are comparable to Kestra Medical Technologies, Ltd. Common Stock?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kestra Medical Technologies, Ltd. Common Stock stock attractive at the current price?
The data as of Nov 10, 2026: price $29.55, calculated fair value $20.23 (−32%), Quality Score 36/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Kestra Medical Technologies, Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kestra Medical Technologies, Ltd. (KMTS)?
The closing price on Nov 10, 2026 was $29.55. Our estimate is $20.23, about 32% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kestra Medical Technologies, Ltd. Common Stock right now?
The price sits above even our optimistic bull case ($25.28). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Kestra Medical Technologies, Ltd.

How large is the market capitalisation of Kestra Medical Technologies, Ltd. (KMTS)?
The market capitalisation of Kestra Medical Technologies, Ltd. is $1.7B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kestra Medical Technologies, Ltd. (KMTS)?
The price-to-sales ratio of Kestra Medical Technologies, Ltd. is 16.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Kestra Medical Technologies, Ltd. (KMTS)?
Earnings per share at Kestra Medical Technologies, Ltd. are $−2.67. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Kestra Medical Technologies, Ltd. (KMTS)?
The dividend yield of Kestra Medical Technologies, Ltd. is 0.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Kestra Medical Technologies, Ltd. (KMTS)?
The net margin of Kestra Medical Technologies, Ltd. is −140% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kestra Medical Technologies, Ltd. (KMTS)?
The return on equity (ROE) of Kestra Medical Technologies, Ltd. is −73.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kestra Medical Technologies, Ltd. (KMTS)?
On an EBIT basis the return on assets of Kestra Medical Technologies, Ltd. is −115% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kestra Medical Technologies, Ltd. (KMTS)?
The operating margin of Kestra Medical Technologies, Ltd. is −122% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kestra Medical Technologies, Ltd. (KMTS)?
Revenue at Kestra Medical Technologies, Ltd. is growing +59.9% versus a year earlier (3y avg +132%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Kestra Medical Technologies, Ltd. (KMTS) generate?
The free cash flow of Kestra Medical Technologies, Ltd. is −$117M (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Kestra Medical Technologies, Ltd. (KMTS) hold?
Kestra Medical Technologies, Ltd. holds more cash than debt, $52.9M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Kestra Medical Technologies, Ltd. Common Stock in the live analysis

One click puts Kestra Medical Technologies, Ltd. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.